A rare combination of double primary malignancies; mixed germ cell tumor of testis with papillary carcinoma of thyroid: a case report

Anuja M. S.; Abdulla K. P.; Arun Chandrasekharan

doi:10.18203/2349-2902.isj20242140

Authors

Anuja M. S. Department of Medical Oncology, Aster MIMS, Govindapuram, Calicut, Kerala, India
Abdulla K. P. Department of Medical Oncology, Aster MIMS, Govindapuram, Calicut, Kerala, India
Arun Chandrasekharan Department of Medical Oncology, Aster MIMS, Govindapuram, Calicut, Kerala, India

DOI:

https://doi.org/10.18203/2349-2902.isj20242140

Keywords:

Double malignancy, Thyroid carcinoma, Testis cancer

Abstract

Double malignancy occurring in multiple organs is relatively rare yet possible. The second primary lesion is identified either simultaneously with the primary lesion (synchronous) or after a while (metachronous). We report a case of synchronous double malignancy in a patient who had two separate carcinomas, a non-seminomatous germ cell tumor (NSGCT) and a papillary carcinoma of thyroid. These types of synchronous double malignancies can be dealt as independent carcinomas. This existence of two carcinomas at anatomically dissimilar sites with distinct histopathologies, being a rare combination, led us to report the case.

Metrics

Metrics Loading ...

References

Chowdary T, Sivaraj S M, Rao G V, Thirunavukkarasu S. Dual malignancies: Do they have a worse prognosis than their individual counterparts. Arch Int Surg. 2015;5(9):29-32.

Billroth T. Die allgemeine chirurgiche pathologie und therapie in 51 varessungen: ein handbuch fur studirende und artz. Berlin: G Riemer. 1889.

Owen LJ. Multiple malignant neoplasms. JAMA. 1921;76:1329-33.

Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med. 2005;46(5):752-7.

Miyazaki T, Sohda M, Higuchi T, Naritaka T, Shigemasa S, Makoto S, et al. Effectiveness of FDG-PET in the screening of synchronous cancer of other organs in patients with esophageal cancer. Anticancer Res. 2014;34(1):283-7.

Gabora K, Bălăcescu O, Trifa A, Morariu AM, Pop B, Vişan S, et al. Thyroid carcinoma associated with other primary neoplasms, a single center study. Med Pharm Rep. 2022;95(3):275-81.

Warren S, Gates O. Multiple primary malignant tumor: a survey of the literature and a statistical study. Am J Cancer. 1932;16:1358-14.

Sang MP, Min KL, Kyu WJ. Pre-diagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol. 2007;25(30):4835-43.

Smith TE, Lee D, Turner BC, Carter D, Haffty BG. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2002;48:1281-9.

Brandon K. Hadland, Longmore GD. Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms. J Clin Oncol. 2009;27:4217-26.

Fossa SD, Langmark F, Aass N, Andersen A, Lothe R, Borrescn AL. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer. 1990;61:639-43.